Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.57 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.50 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30082750 | 1.00 | TFPI (0.57) | TFPIVIPR2VIPR1PTH1ROPRL1 | |
| SCHEMBL29622911 | 0.88 | TFPI (0.62) | TFPIVIPR1OPRL1 | |
| SCHEMBL30421823 | 0.85 | TFPI (0.61) | TFPIVIPR1 | |
| SCHEMBL20764456 | 0.83 | TFPI (0.57) | TFPIOPRL1 | |
| SCHEMBL31031553 | 0.82 | TFPI (0.63) | TFPIVIPR1OPRL1 | |
| SCHEMBL29440667 | 0.82 | TFPI (0.58) | TFPIVIPR2VIPR1NPY1RNPY2R | |
| SCHEMBL29596291 | 0.82 | TFPI (0.66) | TFPIVIPR1EPHA2 | |
| SCHEMBL31430956 | 0.81 | HRAS (0.49) | TFPIVIPR2VIPR1PTH1R | |
| SCHEMBL10743964 | 0.81 | TFPI (0.51) | TFPIOPRL1 | |
| SCHEMBL20764468 | 0.81 | TFPI (0.56) | TFPIVIPR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728279-A2 | USE OF CUSTOM-DESIGNED PEPTIDES FOR MASS CALIBRATION | DH Technologies Development Pte. Ltd. (SG) | 2026-04-22 | — | — | EP | claimed |
| WO-2024257055-A2 | USE OF CUSTOM-DESIGNED PEPTIDES FOR MASS CALIBRATION | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2024-12-19 | — | — | WO | claimed |
| CN-113820385-B | Method and system for rapidly detecting polysorbate compounds | 岛津企业管理（中国）有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-11977074-B2 | Affinity-based detection of ligand-encoded synthetic biomarkers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-05-07 | — | — | US | claimed |
| US-20240102995-A1 | Fluorescence Detection of Circulating Cell Free DNA Including Within Extracellular Vesicles in Biospecimens and Liquid Biopsies | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-28 | — | — | US | claimed |
| WO-2022197659-A2 | FLUORESCENCE DETECTION OF CIRCULATING CELL FREE DNA INCLUDING WITHIN EXTRACELLUALR VESICLES IN BIOSPECIMENS AND LIQUID BIOPSIES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022192448-A1 | ANTIMICROBIAL SYSTEMS AND METHODS THEREOF | TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) | 2022-09-15 | — | — | WO | claimed |
| CN-114509514-A | Method for detecting taurine and arginine in hippocampus trimaculatus by liquid chromatography-electrospray ionization tandem mass spectrometry | 厦门医学院 | 2022-05-17 | — | — | CN | claimed |
| US-20260139040-A2 | PRECISION ACTIVATED POLYPEPTIDES | ABLYNX N.V. (BE) | 2026-05-21 | — | — | US | disclosed |
| US-12631640-B2 | Systems and methods for identifying subtype, prognosis, and monitoring of breast cancer | PURDUE RESEARCH FOUNDATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12618060-B2 | Nucleic acid molecules | CureVac SE (DE) | 2026-05-05 | — | — | US | disclosed |
| EP-3856921-B1 | LUNG PROTEASE NANOSENSORS AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4728279-A2 | USE OF CUSTOM-DESIGNED PEPTIDES FOR MASS CALIBRATION | DH Technologies Development Pte. Ltd. (SG) | 2026-04-22 | — | — | EP | disclosed |
| US-20260077036-A1 | VETERINARY PRODUCT | LETI PHARMA, S.L. (ES) | 2026-03-19 | — | — | US | disclosed |
| EP-3950704-A1 | MULTIPLEXED DETECTION WITH ISOTOPE-CODED REPORTERS | Massachusetts Institute Of Technology (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220033472-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220033471-A1 | METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS | REGENERON PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | disclosed |
| CN-113968901-A | Use of protein sequences that bind to substrates for the preparation of products inhibiting fibrin assembly | 南京大学 | 2022-01-25 | — | — | CN | disclosed |
| CN-115336410-B | Biological product DBT | 广州市众为生物科技股份有限公司 | 2018-09-14 | — | — | CN | disclosed |
| CN-117426158-B | Freeze-drying production process of biological product DBT | 广州市众为生物科技股份有限公司 | 2017-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077036-A1 | VETERINARY PRODUCT | DERL1, VSIG8, CMA1 | TFPI 3269/4885VIPR2 933/4885VIPR1 1158/4885 |
| US-20220033471-A1 | METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS | VEGFA, FLT4, FLT1 | TFPI 1222/4885VIPR2 542/4885VIPR1 563/4885 |
| US-12618060-B2 | Nucleic acid molecules | TP53, MICA, TAP1 | TFPI 2001/4885VIPR2 4025/4885VIPR1 3761/4885 |
| US-20260139040-A2 | PRECISION ACTIVATED POLYPEPTIDES | IGSF11, IGLV6-57, FCGR3B | TFPI 3629/4885VIPR2 1954/4885VIPR1 1491/4885 |
| US-12631640-B2 | Systems and methods for identifying subtype, prognosis, and monitoring of breast cancer | MYH9, MYL12A, BRCA1 | TFPI 1674/4885VIPR2 3580/4885VIPR1 3974/4885 |
| US-20220033472-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | TFPI 2370/4885VIPR2 2692/4885VIPR1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.